UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Clinical genitourinary cancer, 2024-04, Vol.22 (2), p.558-568.e3

2024

Volltextzugriff (PDF)

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Nature communications, 2024-03, Vol.15 (1), p.2790-2790, Article 2790

2024

Volltextzugriff (PDF)

Late Subacute Cerebral Hematoma Mimicking a Metastasis on PSMA PET/CT

Clinical nuclear medicine, 2024-02, Vol.49 (2), p.e70

2024

Volltextzugriff (PDF)

MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease

World journal of urology, 2023-12, Vol.41 (12), p.3889-3894

2023

Volltextzugriff (PDF)

Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5095-5095

2023

Volltextzugriff (PDF)

Defining Patient Benefits from High-intensity Intermittent Therapy for Hormone-sensitive Prostate Cancer

European urology focus, 2023-05, Vol.9 (3), p.419-421

2023

Volltextzugriff (PDF)

Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

The Journal of nuclear medicine (1978), 2023-03, Vol.64 (3), p.349-350

2023

Volltextzugriff (PDF)

Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Journal of Nuclear Medicine, 2023-03, Vol.64 (3), p.349-350

2023

Volltextzugriff (PDF)

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.178-178

2023

Volltextzugriff (PDF)

Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.203-203

2023

Volltextzugriff (PDF)

Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.108-108

2023

Volltextzugriff (PDF)

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Nature communications, 2023-01, Vol.14 (1), p.252-252, Article 252

2023

Volltextzugriff (PDF)

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

Clinical cancer research, 2023-01, Vol.29 (1), p.50-59

2023

Volltextzugriff (PDF)

Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer

Targeting the DNA Damage Response for Cancer Therapy, 2023, Vol.186, p.103-124

2023

Volltextzugriff (PDF)

PP03 Presentation Time: 9:20 AM

Brachytherapy, 2022-11, Vol.21 (6), p.S21

2022

Volltextzugriff (PDF)

PP03 Presentation Time: 9:20 AM: Patterns of Failure for Salvage HDR Prostate Brachytherapy in the Prostate PET Imaging Era

Brachytherapy, 2022-11, Vol.21 (6), p.S21-S21

2022

Volltextzugriff (PDF)

Risk-adaptive paradigm for focal versus whole-gland salvage treatment for radio-recurrent prostate cancer

Frontiers in oncology, 2022-09, Vol.12, p.998390-998390

2022

Volltextzugriff (PDF)

Patterns of structural variation define prostate cancer across disease states

JCI insight, 2022-09, Vol.7 (17)

2022

Volltextzugriff (PDF)

Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer

JCO precision oncology, 2022-08, Vol.6, p.e2200329

2022

Volltextzugriff (PDF)

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

The Prostate, 2022-08, Vol.82 (S1), p.S60-S72

Choudhury, Atish D.

2022

Volltextzugriff (PDF)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

NPJ precision oncology, 2022-06, Vol.6 (1), p.49-49, Article 49

2022

Volltextzugriff (PDF)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-06, Vol.28 (11), p.2257-2269

2022

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(126)

Publikationsform

Sprache

Englisch
(138)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Insulin resistance during androgen deprivation therapy in men with prostate cancer

Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial

A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

FinaleMe: Predicting DNA methylation by the fragmentation patterns of plasma cell-free DNA

Late Subacute Cerebral Hematoma Mimicking a Metastasis on PSMA PET/CT

MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease

Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial

Defining Patient Benefits from High-intensity Intermittent Therapy for Hormone-sensitive Prostate Cancer

Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC)

Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy

Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer

PP03 Presentation Time: 9:20 AM

PP03 Presentation Time: 9:20 AM: Patterns of Failure for Salvage HDR Prostate Brachytherapy in the Prostate PET Imaging Era

Risk-adaptive paradigm for focal versus whole-gland salvage treatment for radio-recurrent prostate cancer

Patterns of structural variation define prostate cancer across disease states

Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Suchergebnisse filtern